Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the ...
Summit Therapeutics Inc. (NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer ...
Tens of thousands of patients could benefit from a ‘rapid’ new immunotherapy jab on the NHS for over a dozen different cancers, which can be given in just 60 seconds.
ASCENT-04 randomized PD-L1–positive, untreated mTNBC to sacituzumab govitecan–pembrolizumab versus chemo–pembrolizumab, yielding a 3.4-month median PFS improvement (HR 0.65). Front-loading an ...
Hosted on MSN
Oncologists explain why they prescribe Keytruda to cancer patients, when and how it works
Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...
With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...
The FDA has approved Keytruda Qlex, an injected version of a popular cancer drug that until now has only been available via infusion. The FDA approved a new injected version of the cancer ...
Keytruda is an immunotherapy drug that is used to treat different types of cancers. The drug helps the body's own immune system to fight the cancer cells. Developed and sold by Merck & Co., the drug ...
The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results